Schedule 13G ownership disclosure

Zentalis Pharmaceuticals, Inc.

Security class unavailable · CUSIP: 98943L107

Event date: 2020-04-07

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
4,443,284
Percent of class
13.0000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001387131-20-003882
Form type
SC 13G
Filer
VIKING GLOBAL INVESTORS LP
CIK
CIK 1103804
Filed
Apr 15, 2020
Reporting period
Apr 07, 2020
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub